BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/24/2022 8:11:15 AM | Browse: 323 | Download: 608
 |
Received |
|
2021-09-15 11:41 |
|
Peer-Review Started |
|
2021-09-15 11:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-10-18 01:24 |
|
Revised |
|
2021-10-27 03:08 |
|
Second Decision |
|
2021-12-13 03:30 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-12-23 03:50 |
|
Articles in Press |
|
2021-12-23 03:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-11 08:56 |
|
Publish the Manuscript Online |
|
2022-01-24 08:11 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhi-Quan Qin, Si-Fu Yang, Yun Chen, Chao-Jin Hong, Tong-Wei Zhao, Guo-Rong Yuan, Liu Yang, Liang Gao, Xiao Wang and Li-Qin Lu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Li-Qin Lu, MD, Professor, Department of Medical Oncology, Zhejiang Provincial People's Hospital (People's Hospital of Hangzhou Medical College), No. 158 Shangtang Road, Xiacheng District, Hangzhou 310014, Zhejiang Province, China. llq199@outlook.com |
| Key Words |
Non-small cell lung cancer; Chemotherapy; Recombinant human endostatin; Continuous intravenous infusion |
| Core Tip |
Lung cancer is one of the malignancies with the highest incidence and mortality worldwide. However, the efficacy and safety of the current regimens is unsatisfactory. Therefore, the development and upgrade of potential therapies that are more effective and less toxic is warranted. This is a retrospective study to investigate the efficacy and safety of 5-d continuous intravenous infusion of Recombinant human endostatin (Rh-endostain) in advanced non-small cell lung cancer (NSCLC) patients. Our results revealed that 5-day continuous intravenous infusion of Rh-endostain using infusion pump improved patient adherence and showed favorable efficacy and safety, which brought significant clinical benefits to advanced NSCLC patients. |
| Publish Date |
2022-01-24 08:11 |
| Citation |
Qin ZQ, Yang SF, Chen Y, Hong CJ, Zhao TW, Yuan GR, Yang L, Gao L, Wang X, Lu LQ. Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer. World J Clin Cases 2022; 10(4): 1164-1171 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i4/1164.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i4.1164 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
